Overview

Transplantation With Ybritumomab Tiuxetan (Zevalin) Plus BEAM Regimen in Patients With Refractory Large B-cell Difusse Lymphom

Status:
Completed

Trial end date:
2012-06-01

Target enrollment:

Participant gender:

Summary

To evaluate the efficacy (complete response rate) of Ybritumomab Tiuxetan (Zevalin) administration in the conditioning treatment of patients with refractory large B-cell diffuse lymphoma submitted to autologous transplantation of peripheral blood haematopoietic stem cells.

Phase:

Phase 2

Details

Lead Sponsor:

Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea

Treatments:

Antibodies, Monoclonal
Melphalan
Rituximab